ticker,date,stage,drug
MYL,10/09/2017,PDUFA,MYL-1401H
ACRX,10/12/2017,PDUFA,ARX-04 (SAP303)
ONCE,10/12/2017,PDUFA priority review,Voretigene neparvovec (SPK-RPE65)
AERI,10/13/2017,PDUFA,Rhopressa
FENC,10/14/2017,Phase 3,Sodium Thiosulphate
JNJ,10/15/2017,PDUFA,STELARA (USTEKINUMAB)
ATRS,10/17/2017,PDUFA,Makena - auto injector
LOXO,10/18/2017,Phase 1,LOXO-292
ATRS,10/20/2017,PDUFA,VIBEX QuickShot
EIGR,10/20/2017,Phase 2,Pegylated Interferon Lambda (LIMT HDV)
JNJ,10/21/2017,PDUFA,SIMPONI ARIA
JNJ,10/21/2017,PDUFA,SIMPONI ARIA
ALXN,10/23/2017,PDUFA,Eculizumab
AGEN,10/24/2017,PDUFA,Shingrix
GSK,10/24/2017,PDUFA,Shingrix
PTCT,10/24/2017,PDUFA,Ataluren
TSRO,10/25/2017,PDUFA,Rolapitant - intravenous (IV)
JNJ,10/28/2017,PDUFA priority review,XARELTO (rivaroxaban)
MNOV,10/28/2017,Phase 2b,MN-166
EGRX,10/30/2017,PDUFA,Ready-to-dilute (RTD) Pemetrexed Injection
DBVT,10/31/2017,Phase 3,Viaskin Peanut (PEPITES)
KERX,11/06/2017,PDUFA,Auryxia
PFE,11/07/2017,PDUFA,Staphylococcus aureus vaccine
BMY,11/09/2017,PDUFA priority review,Sprycel (dasatinib)
DVAX,11/10/2017,PDUFA,HEPLISAV-B
CALA,11/11/2017,Phase 1/2,CB-839 + nivolumab
HRTX,11/12/2017,PDUFA,CINVANTI (HTX-019)
ARDX,11/15/2017,Phase 3,Tenapanor (T3MPO-2)
RARE,11/16/2017,PDUFA priority review,rhGUS
GILD,11/29/2017,PDUFA priority review,Axicabtagene ciloleucel (KTE-C19) - ZUMA-1
CLDX,11/30/2017,Phase 2,"Glembatumumab vedotin, varlilumab, Opdivo or Keytruda"
AMGN,12/02/2017,PDUFA,Repatha
MYL,12/03/2017,PDUFA,MYL-1401O - trastuzumab biosimilar
GSK,12/05/2017,PDUFA priority review,Dolutegravir + rilpivirine:
JNJ,12/05/2017,PDUFA priority review,Rilpivirine and Dolutegravir
NVO,12/05/2017,PDUFA,Semaglutide
ARGX,12/09/2017,Phase 2,ARGX-110
ARGX,12/09/2017,Phase 1/2,ARGX-110
BLUE,12/09/2017,Phase 1/2,LentiGlobin - HGB-206
IMDZ,12/09/2017,Phase 2,G100
STML,12/12/2017,Phase 2,SL-401
STML,12/12/2017,Phase 2,SL-401
SGEN,12/16/2017,PDUFA priority review,ADCETRIS
ACRS,12/24/2017,PDUFA,A-101
AGRX,12/26/2017,PDUFA,Twirla
CORI,12/26/2017,PDUFA,Twirla
VRX,12/27/2017,PDUFA,Luminesse
AEZS,12/30/2017,PDUFA,Macimorelin Acetate - Macrilen
ABBV,12/31/2017,Phase 3,Risankizumab
ABBV,12/31/2017,Phase 3,Elagolix
ABBV,12/31/2017,Phase 2b,Risankizumab
ABBV,12/31/2017,Phase 2,Rova-T (TRINITY)
ADRO,12/31/2017,Phase 2,CRS-207 with pembrolizumab
AFMD,12/31/2017,Phase 1b,AFM13 with Keytruda
ALKS,12/31/2017,Phase 3,ALKS 8700
ANAB,12/31/2017,Phase 2,ANB020
ANAB,12/31/2017,Phase 2a,ANB020
ARDX,12/31/2017,Phase 2,RDX7675
ARGS,12/31/2017,Phase 2,rocapuldencel-T (AGS-003)
AST,12/31/2017,Phase 1/2,AST-OPC1 SCiSTAR
ATNM,12/31/2017,Phase 2,Actimab-A
ATNX,12/31/2017,Phase 3,Oraxol
AXON,12/31/2017,Phase 2b,Intepirdine - HEADWAY-DLB
AXON,12/31/2017,Phase 2,Nelotanserin
AZN,12/31/2017,Phase 3,Tralokinumab (STRATOS2)
AZN,12/31/2017,Phase 3,Moxetumomab
AZN,12/31/2017,Phase 3,Durvalumab +/- tremelimumab (ARCTIC)
BIIB,12/31/2017,Phase 2,BAN2401 (Aβ mAb)
BIIB,12/31/2017,Phase 2,BG00011 (STX-100)
BLRX,12/31/2017,Phase 2,BL-8040 in combination with KEYTRUDA - COMBAT trial
BMY,12/31/2017,Phase 3,CM-459 – Opdivo
BMY,12/31/2017,Phase 3,CM-511 – Opdivo + Yervoy
BMY,12/31/2017,Phase 3,CM-227 – Opdivo + Yervoy
BOLD,12/31/2017,Phase 1/2,AT342 - VALENS
BOLD,12/31/2017,Phase 1/2,AT132 - ASPIRO
BPTH,12/31/2017,Phase 2,BP-1001
BTX,12/31/2017,Phase 1/2,AST-OPC1 - SCiStar
BYSI,12/31/2017,Phase 2/3,Plinabulin (Trial 105)
CALA,12/31/2017,Phase 2,CB-839 with paclitaxel
CBIO,12/31/2017,Phase 1/2,CB 2679d/ ISU304
CDTX,12/31/2017,Phase 2,CD101 IV - STRIVE
CELG,12/31/2017,Phase 3,REVLIMID - RELEVANCE
CELG,12/31/2017,Phase 3,REVLIMID - AUGMENT NHL-007
CELG,12/31/2017,Phase 3,ABRAXANE - PANC-003 apact
CELG,12/31/2017,Phase 2,OTEZLA
CELG,12/31/2017,Phase 2,GED-0301
CEMP,12/31/2017,Phase 2/3,Taksta - Fusidic acid
CLRB,12/31/2017,Phase 2,CLR 131
CLSD,12/31/2017,Phase 1/2,Suprachoroidal CLS-TA - HULK
CPRX,12/31/2017,Phase 3,Firdapse
CRBP,12/31/2017,Phase 2,Anabasum (Resunab)
CRMD,12/31/2017,Phase 3,Neutrolin - LOCK-IT 100
CYTK,12/31/2017,Phase 3,Tirasemtiv - VITALITY
DBVT,12/31/2017,Phase 3,Viaskin Peanut (REALISE)
DCTH,12/31/2017,Phase 3,Melphalan Hepatic Delivery System (Melphalan HDS)
DMTX,12/31/2017,Phase 1/2,DTX301
DRRX,12/31/2017,Phase 3,POSIMIR - PERSIST 3
EARS,12/31/2017,Phase 3,AM-111 HEALOS
EVOK,12/31/2017,Phase 3,Gimoti - EVK-001
EXEL,12/31/2017,Phase 3,XL184 cabozantinib (CELESTIAL)
EYEG,12/31/2017,Phase 2b,EGP-437
FBIO,12/31/2017,Phase 1/2,CAEL‐101
GALT,12/31/2017,Phase 2b,GR-MD-02
GBT,12/31/2017,Phase 2a,GBT440
GBT,12/31/2017,Phase 2a,GBT440 HOPE-KIDS 1
GILD,12/31/2017,Phase 2,GS-9674
GILD,12/31/2017,Phase 2,GS-0976
GNMX,12/31/2017,Phase 1/2,AEVI-002 (Anti-LIGHT mAb)
GSK,12/31/2017,Phase 2b,anti-SAP mAb
GSK,12/31/2017,Phase 2b,GSK 166
GSK,12/31/2017,Phase 2,GSK 165
HALO,12/31/2017,Phase 1b,PEGPH20 in combination with KEYTRUDA
IMRN,12/31/2017,Phase 2,IMM-124E
IONS,12/31/2017,Phase 1/2,IONIS-HTT Rx
IRWD,12/31/2017,Phase 2a,IW-1973
IRWD,12/31/2017,Phase 2,IW-1973
KDMN,12/31/2017,Phase 2,KD025
KMDA,12/31/2017,Phase 2/3,Alpha-1 Antitrypsin (AAT)
LLY,12/31/2017,Phase 3,Flortaucipir F 18 (Tau imaging agent)
LLY,12/31/2017,Phase 3,Alimta + Keytruda (MK-3475-189/KEYNOTE-189)
LLY,12/31/2017,Phase 3,Abemaciclib - JUNIPER
LOXO,12/31/2017,Phase 2,Larotrectinib (LOXO-101)
MBVX,12/31/2017,Phase 1,MVT-1075
MDGL,12/31/2017,Phase 2,MGL-3196
MESO,12/31/2017,Phase 3,MSC-100-IV
MRK,12/31/2017,Phase 3,(MK-3475-189/KEYNOTE-189)
MRK,12/31/2017,PDUFA,Ertugliflozin
MRNS,12/31/2017,Phase 2,Ganaxolone
MRSN,12/31/2017,Phase 1,XMT1522
MRTX,12/31/2017,Phase 2,Mocetinostat and durvalumab
MRTX,12/31/2017,Phase 2,Glesatinib (MGCD265)
MRUS,12/31/2017,Phase 1/2,MCLA-128
NBIX,12/31/2017,Phase 3,Elagolix
NKTR,12/31/2017,Phase 3,Inhaled Amikacin Solution (BAY41-6551T)
NLNK,12/31/2017,Phase 2,Indoximod + gemcitabine and nab-paclitaxel
NVAX,12/31/2017,Phase 1/2,NanoFlu vaccine
NVS,12/31/2017,Phase 3,LEE011: MONALEESA-3
OCRX,12/31/2017,Phase 2a,OCR-002
OGEN,12/31/2017,Phase 2,AG013
ONCS,12/31/2017,Phase 2,ImmunoPulse IL-12 - PISCES
ONTX,12/31/2017,Phase 3,IV Rigosertib - INSPIRE
PBYI,12/31/2017,Phase 2,Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL
PFE,12/31/2017,Phase 3,Xeljanz
PFE,12/31/2017,Phase 3,Ertugliflozin
PFE,12/31/2017,PDUFA priority review,BOSULIF
PHMMF,12/31/2017,Phase 3,Zepsyre(PM1183)
PLX,12/31/2017,Phase 2,OPRX-106
PTI,12/31/2017,Phase 2,PTI-428
RDUS,12/31/2017,Phase 2b,Elacestrant
REGN,12/31/2017,Phase 2,EYLEA + nesvacumab
REGN,12/31/2017,Phase 2,EYLEA + nesvacumab
RETA,12/31/2017,Phase 2,Bardoxolone methyl - LARIAT
RETA,12/31/2017,Phase 2,Omaveloxolone - MOTOR
RETA,12/31/2017,Phase 1/2,Omaveloxolone - REVEAL
RGLS,12/31/2017,Phase 1/2,RG-012
RGNX,12/31/2017,Phase 1/2,RGX-501
RNN,12/31/2017,Phase 2a,Supinoxin
RNN,12/31/2017,Phase 2,RX-3117
RNN,12/31/2017,Phase 2a,Archexin
RVNC,12/31/2017,Phase 2,RT002 - SAKURA 2
RVNC,12/31/2017,Phase 2,RT002
RVNC,12/31/2017,Phase 3,RT002 - SAKURA 1
RXDX,12/31/2017,Phase 2,STARTRK-2 entrectinib
RXII,12/31/2017,Phase 2,RXI-109-1402
RXII,12/31/2017,Phase 2,Samcyprone - RXI-SCP-1502
RYTM,12/31/2017,Phase 2,Setmelanotide
SAGE,12/31/2017,Phase 3,Brexanolone - SAGE-547 (202C)
SAGE,12/31/2017,Phase 2,SAGE-217
SAGE,12/31/2017,Phase 2,SAGE-217
SAGE,12/31/2017,Phase 2,SAGE-217
SAGE,12/31/2017,Phase 3,Brexanolone - SAGE-547 (202B)
SAGE,12/31/2017,Phase 2,SAGE-217
SPPI,12/31/2017,Phase 2,Poziotinib
STML,12/31/2017,Phase 2,SL-401
TCON,12/31/2017,Phase 2,TRC105 and Inlyta
TCON,12/31/2017,Phase 2,TRC105
TSRO,12/31/2017,Phase 2,Niraparib - (QUADRA trial)
VKTX,12/31/2017,Phase 2,VK5211
VNDA,12/31/2017,Phase 2,HETLIOZ (tasimelteon)
VRTX,12/31/2017,Phase 2,CTP-656
VRTX,12/31/2017,Phase 3,Tezacaftor (VX-661) / ivacaftor
VRX,12/31/2017,Phase 2,SAN-300
XBIT,12/31/2017,Phase 2,Xilonix
XLRN,12/31/2017,Phase 2,ACE-083
XNCR,12/31/2017,Phase 2,XmAb5871
XENT,01/07/2018,PDUFA,RESOLVE steroid-releasing implant
EIGR,01/08/2018,Phase 2,Ubenimex - LIBERTY
LLY,01/10/2018,PDUFA priority review,Abemaciclib - MONARCH 1 and 2
AXSM,01/15/2018,Phase 3,AXS-02 CREATE-1
AXSM,01/15/2018,Phase 3,AXS-02 COAST-1
SGYP,01/24/2018,PDUFA,Trulance (plecanatide)
AAAP,01/26/2018,PDUFA,Lutathera
ARDM,01/26/2018,PDUFA priority review,Linhaliq (Pulmaquin)
SCMP,01/28/2018,PDUFA,Lubiprostone
PFE,01/31/2018,Phase 3,Talazoparib
AZN,02/01/2018,PDUFA priority review,Acalabrutinib
AMAG,02/02/2018,PDUFA,Feraheme
PTLA,02/02/2018,PDUFA,Andexanet alfa
AMGN,02/03/2018,PDUFA,XGEVA
LPCN,02/08/2018,PDUFA,LPCN 1021
GILD,02/12/2018,PDUFA priority review,Bictegravir/F/TAF
AMAG,02/14/2018,PDUFA,Makena - auto injector
APRI,02/17/2018,PDUFA,Vitaros
KMPH,02/23/2018,PDUFA,KP201/APAP
LJPC,02/28/2018,PDUFA priority review,LJPC-501
MDGL,02/28/2018,Phase 2,MGL-3196
SRNE,02/28/2018,PDUFA,ZTlido (lidocaine patch 1.8%)
VRTX,02/28/2018,PDUFA priority review,Tezacaftor (VX-661) / ivacaftor
OTIC,03/02/2018,PDUFA,OTIPRIO
BMY,03/05/2018,PDUFA,Opdivo -  4 week applications
PFE,03/13/2018,PDUFA,Xeljanz
ABIO,03/31/2018,Phase 2b,Gencaro - GENETIC-AF trial
ACOR,03/31/2018,Phase 3,Tozadenant
AIMT,03/31/2018,Phase 3,AR101
ANTH,03/31/2018,Phase 3,Sollpura - RESULT
ARGX,03/31/2018,Phase 2,ARGX-113
ARNA,03/31/2018,Phase 2,APD371
ARNA,03/31/2018,Phase 2,Etrasimod
AVEO,03/31/2018,Phase 3,TIVO-3 - tivozanib
AXON,03/31/2018,Phase 2,Nelotanserin
AXSM,03/31/2018,Phase 3,AXS-05 STRIDE-1
AZN,03/31/2018,Phase 3,Brilinta (THEMIS)
CLBS,03/31/2018,Phase 2,CLBS03
CLSD,03/31/2018,Phase 3,Suprachoroidal CLS-TA - PEACHTREE
CORI,03/31/2018,Phase 3,Corplex Donepezil
CORT,03/31/2018,Phase 2,CORT125134
CYTK,03/31/2018,Phase 2,CK-2127107
DERM,03/31/2018,Phase 3,Olumacostat glasaretil (DRM01)
EARS,03/31/2018,Phase 3,Keyzilen (AM-101) - TACTT3
ESPR,03/31/2018,Phase 2,Bempedoic Acid - 1002-039
FGEN,03/31/2018,Phase 2,Pamrevlumab (FG-3019)
GALE,03/31/2018,Phase 2b,NeuVax in combination with Herceptin
GEMP,03/31/2018,Phase 2b,Gemcabene - INDIGO-1
GERN,03/31/2018,Phase 2,Imetelstat - IMbarkStudy
GSK,03/31/2018,Phase 3,Dolutegravir + lamivudine (GEMINI 1)
GTHX,03/31/2018,Phase 2,Trilaciclib
GTHX,03/31/2018,Phase 2,Trilaciclib
GTHX,03/31/2018,Phase 2,Trilaciclib
GWPH,03/31/2018,Phase 2,GWP42006 (CBDV)
MBIO,03/31/2018,Phase 1,MB-102
MBIO,03/31/2018,Phase 1,MB-101
MCRB,03/31/2018,Phase 1b,SER-262
MEIP,03/31/2018,Phase 2,Pracinostat in combination with Vidaza
MESO,03/31/2018,Phase 2b,MPC-150-IM
MYOK,03/31/2018,Phase 2,MYK-461 - PIONEER-HCM
OBSV,03/31/2018,Phase 2,OBE001 - IMPLANT2
OHRP,03/31/2018,Phase 3,OHR-102 (MAKO)
PFE,03/31/2018,Phase 3,Tanezumab
PFE,03/31/2018,Phase 3,Tanezumab
PTGX,03/31/2018,Phase 2b,PTG-100
REGN,03/31/2018,Phase 3,Praluent (alirocumab) ODYSSEY OUTCOMES
RXII,03/31/2018,Phase 1/2,RXI-109-1501
SGMO,03/31/2018,Phase 1/2,SB-318
SGMO,03/31/2018,Phase 1/2,SB-FIX
SGMO,03/31/2018,Phase 1/2,SB-913
SMMT,03/31/2018,Phase 2,Ezutromid
SNY,03/31/2018,Phase 2,SAR439684 (PD-1)
SNY,03/31/2018,Phase 3,Praluent (alirocumab) ODYSSEY OUTCOMES
SPHS,03/31/2018,Phase 2,Topsalysin (PRX302)
SPPI,03/31/2018,Phase 3,SPI-2012 (ROLONTIS)
TTPH,03/31/2018,Phase 3,Eravacycline (TP-434) - IGNITE3
VBLT,03/31/2018,Phase 3,VB-111
VICL,03/31/2018,Phase 2,VCL-HB01 HSV-2 Therapeutic Vaccine
VICL,03/31/2018,Phase 3,ASP0113 Vaccine
VTVT,03/31/2018,Phase 3,Azeliragon - STEADFAST
RIGL,04/17/2018,PDUFA,Fostamatinib
AMGN,04/30/2018,PDUFA,KYPROLIS (ENDEAVOR)
KPTI,04/30/2018,Phase 2b,Selinexor - STORM
NBRV,04/30/2018,Phase 3,Lefamulin - LEAP 2
AMGN,05/17/2018,PDUFA,Erenumab
NVS,05/17/2018,PDUFA,Erenumab
REPH,05/26/2018,PDUFA,Intravenous (IV) meloxicam
KTOV,05/31/2018,PDUFA,KIT-302
AGN,06/30/2018,Phase 2b,ATOGEPANT
AGN,06/30/2018,Phase 3,UBROGEPANT
ALRN,06/30/2018,Phase 2a,ALRN-6924
ALXN,06/30/2018,Phase 3,ALXN1210
AMGN,06/30/2018,Phase 3,ABP 798
ANAB,06/30/2018,Phase 2a,ANB020
ARRY,06/30/2018,PDUFA,Binimetinib - COLUMBUS
AVIR,06/30/2018,Phase 2,BTA074 5% topical gel
AZN,06/30/2018,Phase 3,Lynparza
AZN,06/30/2018,Phase 3,Durvalumab +/- tremelimumab (MYSTIC)
AZN,06/30/2018,Phase 3,Durvalumab +/- tremelimumab (KESTREL)
AZN,06/30/2018,Phase 3,Durvalumab +/- tremelimumab (EAGLE)
BHVN,06/30/2018,Phase 3,Rimegepant
BMY,06/30/2018,Phase 3,CM-651 – Opdivo + Yervoy
BMY,06/30/2018,Phase 3,CM-451 – Opdivo + Yervoy
BMY,06/30/2018,Phase 3,CM-331– Opdivo
BMY,06/30/2018,Phase 3,CM-078 – Opdivo
BMY,06/30/2018,Phase 2,CM-548 - Opdivo+SOC
BYSI,06/30/2018,Phase 2/3,Plinabulin (Trial 106)
CLDX,06/30/2018,Phase 2b,Glembatumumab vedotin
CLSD,06/30/2018,Phase 2,Suprachoroidal CLS-TA - TYBEE
CNAT,06/30/2018,Phase 2b,Emricasan
CPRX,06/30/2018,Phase 3,Firdapse
CTIC,06/30/2018,Phase 3,PIXUVRI - PIX306 Trial
DBVT,06/30/2018,Phase 2b,Viaskin Milk
EIGR,06/30/2018,Phase 2,Ubenimex - ULTRA
ESPR,06/30/2018,Phase 3,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048"
ESPR,06/30/2018,Phase 3,Bempedoic acid (ETC-1002-040) - Clear Harmony
EYEG,06/30/2018,Phase 3,EGP-437
FBIO,06/30/2018,Phase 2,CEVA101
FBIO,06/30/2018,Phase 2,Pepvax vaccine
FBIO,06/30/2018,Phase 3,IV Tramadol
FLKS,06/30/2018,Phase 2,FLX-787
FOMX,06/30/2018,Phase 3,FMX101 - FX2017-22
GLMD,06/30/2018,Phase 2b,Aramchol - ARREST
GTHX,06/30/2018,Phase 1b,G1T38 plus Faslodex
IDRA,06/30/2018,Phase 2,IMO-8400
JNCE,06/30/2018,Phase 1/2,JTX-2011
JNJ,06/30/2018,Phase 3,Esketamine
KURA,06/30/2018,Phase 2,Tipifarnib
KURA,06/30/2018,Phase 2,Tipifarnib
MACK,06/30/2018,Phase 2,MM-141 - CARRIE
MDWD,06/30/2018,Phase 3,NexoBrid
MTNB,06/30/2018,Phase 2,MAT2501
NVCR,06/30/2018,Phase 2,Tumor Treating Fields (TTFields) STELLAR
OCUL,06/30/2018,Phase 3,OTX-TP
PBYI,06/30/2018,Phase 3,Neratinib
PRTA,06/30/2018,Phase 2b,NEOD001 PRONTO
PSTI,06/30/2018,Phase 2,PLX-PAD (stem cells)
RNN,06/30/2018,Phase 2a,RX-3117 in combination with Abraxane
RXDX,06/30/2018,Phase 1b,RXDX-105
RYTM,06/30/2018,Phase 2,Setmelanotide
RYTM,06/30/2018,Phase 2,Setmelanotide
RYTM,06/30/2018,Phase 2,Setmelanotide
SBBP,06/30/2018,Phase 3,COR-003 (levoketoconazole) - SONICS
SNDX,06/30/2018,Phase 3,E2112
SNGX,06/30/2018,Phase 3,SGX301 (synthetic hypericin)
SVRA,06/30/2018,Phase 2,Aironite - INDIE
TBPH,06/30/2018,Phase 2a,TD-9855
TGTX,06/30/2018,Phase 3,TG-1101 and TGR-1202 - UNITY-CLL study
TNXP,06/30/2018,Phase 3,TNX-102 SL
TOCA,06/30/2018,Phase 2/3,Toca 511 & Toca FC
VKTX,06/30/2018,Phase 2,VK2809
VNDA,06/30/2018,Phase 2,Tradipitant
VTGN,06/30/2018,Phase 2,AV-101
ZFGN,06/30/2018,Phase 2,ZGN-1061
ZGNX,06/30/2018,Phase 3,ZX008 - Study 1504
ALNY,07/31/2018,Phase 3,Givosiran
CELG,07/31/2018,Phase 3,Luspatercept - BELIEVE
CELG,07/31/2018,Phase 3,Luspatercept - MEDALIST
EBIO,07/31/2018,Phase 3,Vicinium
FOMX,07/31/2018,Phase 3,FMX103
GNMX,07/31/2018,Phase 2,AEVI-001 (NFC-1)
LLY,07/31/2018,Phase 3,Ramucirumab
OBSV,07/31/2018,Phase 2b,OBE2109 - EDELWEISS
RGLS,07/31/2018,Phase 2,RG-012 - HERA
SCYX,07/31/2018,Phase 2,SCY-078 - oral
VTL,07/31/2018,Phase 3,VTI-308
XLRN,07/31/2018,Phase 3,Luspatercept - MEDALIST
XLRN,07/31/2018,Phase 3,Luspatercept - BELIEVE
BLRX,08/31/2018,Phase 2,BL-8040
RDHL,08/31/2018,Phase 3,RHB-104 MAP US
TCON,08/31/2018,Phase 3,TRC105 (TAPPAS)
AGTC,09/30/2018,Phase 1/2,rAAV-hRS1
AMRN,09/30/2018,–,Vascepa REDUCE-IT outcomes trial
AQXP,09/30/2018,Phase 3,AQX-1125 LEADERSHIP
HSGX,09/30/2018,Phase 3,NeoCart
SBBP,09/30/2018,Phase 3,COR-003 (levoketoconazole) - LOGICS
CNCE,09/30/2018,Phase 3,AVP-786
ADXS,12/31/2018,Phase 1/2,ADXS-PSA and Keytruda
AGLE,12/31/2018,Phase 1/2,AEB1102
AGN,12/31/2018,Phase 2b,Brazikumab
AGN,12/31/2018,Phase 3,Cariprazine
AGN,12/31/2018,Phase 3,ABICIPAR
AKBA,12/31/2018,Phase 3,Vadadustat - TRILO2GY
AKBA,12/31/2018,Phase 2,Vadadustat - FO2RWARD
ALDX,12/31/2018,Phase 3,ADX-102
ALDX,12/31/2018,Phase 2,ADX-102
ALKS,12/31/2018,Phase 3,ALKS 3831 - ENLIGHTEN-2
ALNY,12/31/2018,Phase 1/2,ALN-CC5 (cemdisiran)
ALXN,12/31/2018,Phase 3,Eculizumab
ANIK,12/31/2018,Phase 3,Cingal
ARGS,12/31/2018,Phase 2,ARGX-113
ARGX,12/31/2018,Phase 2,ARGX-113
AZN,12/31/2018,Phase 3,Dapagliflozin - DECLARE
AZN,12/31/2018,Phase 3,Benralizumab - TERRANOVA
AZN,12/31/2018,Phase 3,Farxiga - DECLARE
AZN,12/31/2018,Phase 3,Selumetinib - ASTRA
AZN,12/31/2018,Phase 3,Roxadustat - ANDES
AZN,12/31/2018,Phase 3,PT010
AZN,12/31/2018,Phase 3,Durvalumab +/- tremelimumab (NEPTUNE)
AZN,12/31/2018,Phase 3,Durvalumab +/- tremelimumab (DANUBE)
AZN,12/31/2018,Phase 3,Anifrolumab
BIIB,12/31/2018,Phase 2,Raxatrigine - BIIB074 (Nav1.7 inhibitor)
BLPH,12/31/2018,Phase 3,INOpulse delivery device
BLRX,12/31/2018,Phase 2b,BL-8040
BMY,12/31/2018,Phase 3,CM-602 – Opdivo + Elo + SOC
BYSI,12/31/2018,Phase 3,Plinabulin
CELG,12/31/2018,Phase 3,REVLIMID - ROBUST
CELG,12/31/2018,Phase 3,MM-007 OPTIMISMM
CELG,12/31/2018,Phase 3,Ozanimod - TRUE NORTH
CELG,12/31/2018,Phase 3,OTEZLA - BCT-002 RELIEF
CELG,12/31/2018,Phase 3,GED-0301 (CD-003)
CELG,12/31/2018,Phase 3,GED-0301 (CD-002)
CELG,12/31/2018,Phase 3,Oral Azacitidine - CC-486-AML-001
CELG,12/31/2018,Phase 3,ABRAXANE - IMpower 131 ( I/O Combo)
CELG,12/31/2018,Phase 3,ABRAXANE - IMpower 130 ( I/O Combo)
CELG,12/31/2018,Phase 3,ABRAXANE - IMPassion ( I/O Combo)
CFRX,12/31/2018,Phase 2,CF-301
CNAT,12/31/2018,Phase 2,Emricasan
CNCE,12/31/2018,Phase 2a,CTP-543
EARS,12/31/2018,Phase 3,AM-111 ASSENT
EPZM,12/31/2018,Phase 2,Tazemetostat
FGEN,12/31/2018,Phase 3,Roxadustat - ANDES
FLKS,12/31/2018,Phase 2,FLX-787 (Aust)
GEMP,12/31/2018,Phase 2,Gemcabene - AZURE-1
GILD,12/31/2018,Phase 2,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2)
GILD,12/31/2018,Phase 1/2,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3)
GILD,12/31/2018,Phase 1/2,Axicabtagene ciloleucel - KTE-C19 (ZUMA-4)
GSK,12/31/2018,Phase 3,Closed Triple - CAPTAIN
GWPH,12/31/2018,Phase 3,Epidiolex
IMGN,12/31/2018,Phase 3,Kadcyla (KATHERINE).
IMRN,12/31/2018,Phase 1/2,IMM-529
INCY,12/31/2018,Phase 3,Epacadostat with Keytruda - ECHO-301
INVA,12/31/2018,Phase 3,Closed Triple
IOVA,12/31/2018,Phase 2,LN-145
JNJ,12/31/2018,Phase 3,STELARA (USTEKINUMAB)
JNJ,12/31/2018,Phase 3,DARZALEX (Daratumumab)
KALA,12/31/2018,Phase 3,KPI‑121 0.25%
KALA,12/31/2018,Phase 3,KPI‑121 0.25%
KPTI,12/31/2018,Phase 2b,Selinexor - SADAL
MACK,12/31/2018,Phase 2,MM-121
MBRX,12/31/2018,Phase 1/2,Annamycin
MRK,12/31/2018,Phase 3,Epacadostat with Keytruda - ECHO-301
NVS,12/31/2018,Phase 3,QVM149
NVS,12/31/2018,Phase 3,LEE011: MONALEESA-7
NVS,12/31/2018,Phase 3,Entresto - PIONEER
NVS,12/31/2018,Phase 3,Entresto - PARAGON
NVS,12/31/2018,Phase 3,AIN457 (Cosentyx)
OBSV,12/31/2018,Phase 2a,OBE022 - PROLONG
PFE,12/31/2018,Phase 3,Tanezumab
PLX,12/31/2018,Phase 3,PRX-102
PULM,12/31/2018,Phase 2,PUR1800
RETA,12/31/2018,Phase 3,Bardoxolone methyl - CATALYST
RIGL,12/31/2018,Phase 2,Fostamatinib
SGEN,12/31/2018,Phase 3,ADCETRIS in combination with chemotherapy - ECHELON-2
SNNA,12/31/2018,Phase 3,SNA-001
SNNA,12/31/2018,Phase 3,SNA-001
SVRA,12/31/2018,Phase 3,Molgradex - IMPALA
TBPH,12/31/2018,Phase 3,Closed Triple - CAPTAIN
TCON,12/31/2018,Phase 2,TRC105 and Nexavar
TCON,12/31/2018,Phase 2,TRC105
TCON,12/31/2018,Phase 2,TRC102
UTHR,12/31/2018,Phase 3,Esuberaprost - BEAT
UTHR,12/31/2018,Phase 3,Orenitram
VNDA,12/31/2018,Phase 3,HETLIOZ (tasimelteon)
VRNA,12/31/2018,Phase 2b,RPL554
VTGN,12/31/2018,Phase 2,AV-101
CLSN,03/31/2019,Phase 3,ThermoDox - OPTIMA
GSK,03/31/2019,Phase 2b,Danirixin
PRTO,03/31/2019,Phase 3,Vonapanitase (PRT-201) PATENCY-2
XNCR,03/31/2019,Phase 2,XmAb5871
ABBV,06/30/2019,Phase 2,ABBV-8E12
ATNM,06/30/2019,Phase 3,Iomab-B
BMY,06/30/2019,Phase 2,CM-568 - Opdivo + Yervoy
CNAT,06/30/2019,Phase 2,Emricasan
FBIO,06/30/2019,Phase 2,CEVA101
GBT,06/30/2019,Phase 3,GBT440 - HOPE
GSK,06/30/2019,Phase 3,Tapinarof
GSK,06/30/2019,Phase 2b,Inhaled PI3Kδ inhibitor
ICPT,06/30/2019,Phase 3,Obeticholic acid (OCA) - REGENERATE
RYTM,06/30/2019,Phase 3,Setmelanotide
TBPH,06/30/2019,Phase 3,Telavancin
AKBA,07/31/2019,Phase 3,Vadadustat - INNO2VATE
AKBA,07/31/2019,Phase 3,Vadadustat - PRO2TECT
ABBV,12/31/2019,Phase 3,Venetoclax
AFMD,12/31/2019,Phase 2,AFM13
AGN,12/31/2019,Phase 3,RAPASTINEL
ALNY,12/31/2019,Phase 3,Inclisiran
ALNY,12/31/2019,Phase 3,Fitusiran (ATLAS)
AZN,12/31/2019,Phase 3,AZD3293
CELG,12/31/2019,Phase 3,REVLIMID - MAGNIFY NHL-010
CHMA,12/31/2019,Phase 3,Mycapssa - OPTIMAL
CNAT,12/31/2019,Phase 2b,Emricasan
CRBP,12/31/2019,Phase 3,Anabasum (Resunab)
GALE,12/31/2019,Phase 2,NeuVax in combination with Herceptin
GSK,12/31/2019,Phase 3,Mepolizumab - SYNAPSE
IMGN,12/31/2019,Phase 3,Kadcyla (KAITLIN)
JNJ,12/31/2019,Phase 3,INVOKANA - CREDENCE
JNJ,12/31/2019,Phase 3,DARZALEX (Daratumumab)
KPTI,12/31/2019,Phase 2/3,Selinexor - SEAL
KPTI,12/31/2019,Phase 3,Selinexor - BOSTON
LLY,12/31/2019,Phase 3,AZD3293
MDCO,12/31/2019,Phase 3,Inclisiran
MRK,12/31/2019,Phase 3,MK-8931 (019) - Verubecestat
NVS,12/31/2019,Phase 3,QAW039 (fevipiprant)
NVS,12/31/2019,Phase 3,OMB157 (ofatumumab)
NVS,12/31/2019,Phase 3,Entresto - PARADISE
RETA,12/31/2019,Phase 3,Bardoxolone methyl - CARDINAL
SNY,12/31/2019,Phase 3,Fitusiran (ATLAS)
ABBV,06/30/2020,Phase 2,ABBV-8E12
ADXS,06/30/2020,Phase 3,Axalimogene filolisbac - AIM2CERV Trial
OBSV,06/30/2020,Phase 3,OBE2109 - PRIMROSE
AGN,12/31/2020,Phase 3,RELAMORELIN
CELG,12/31/2020,Phase 3,REVLIMID - MAGNIFY NHL-008
CHMA,12/31/2020,Phase 3,Mycapssa - MPOWERED
GSK,12/31/2020,Phase 3,Daprodustat - ASCEND-D
INCY,12/31/2020,Phase 3,Ruxolitinib - REACH 2
NVCR,12/31/2020,Phase 3,Tumor Treating Fields (TTFields) METIS
NVS,12/31/2020,Phase 3,Ruxolitinib - REACH 2
PFE,12/31/2020,Phase 3,XTANDI
PFE,06/30/2021,Phase 3,XTANDI (EMBARK)
NVCR,12/31/2021,Phase 3,Tumor Treating Fields (TTFields) LUNAR
AMGN,12/31/2023,Phase 2/3,CNP 520
NVS,12/31/2023,Phase 2/3,CNP 520
